With one of the largest, most robust pipelines in the industry — including more than 120 research projects and product candidates — we comprise nearly half of AstraZeneca’s overall R&D portfolio. We are focused on three core therapeutic areas: Oncology; Respiratory, Inflammation and Autoimmune; and Cardiovascular and Metabolic Disease. But, we also are opportunity-driven in Infectious Disease.
Combining biology and computer science, Bioinformatics offers an unprecedented window into human disease—giving us essential knowledge about the human immune system. What we learn about this landscape of genes, proteins, cells and systems is critical toward customizing therapies to the unique molecular needs of patients.